CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia (Q38813257)

6 September 2017

title

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia (English)

1 reference

6 September 2017

0 references

1 reference

lymphoblastic leukemia

1 reference

3

Stephan A Grupp

1 reference

6 September 2017

2

Noelle V Frey

1 reference

6 September 2017

Nathan Singh

1

1 reference

6 September 2017

Shannon L Maude

series ordinal

4

1 reference

6 September 2017

publication date

1 June 2016

1 reference

Current Treatment Options in Oncology

6 September 2017

published in

1 reference

6 September 2017

volume

17

1 reference

6 September 2017

issue

6

1 reference

6 September 2017

page(s)

28

1 reference

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

4-1BB chimeric antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Chimeric antigen receptor therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

The myth of the second remission of acute leukemia in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Acute Lymphoblastic Leukemia in Children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Relapsed childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Toxicity management for patients receiving novel T-cell engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Hemophagocytic lymphohistiocytosis: updates and evolving concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Treatment of advanced leukemia in mice with mRNA engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Characterization of CD22 expression in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-016-0406-4

Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27098534

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11864-016-0406-4

1 reference

Dimensions Publication ID

6 September 2017

1010808946

0 references

1 reference